Abstract
Drug-discrimination procedures empirically evaluate the control that internal drug states exert over behavior. They provide a highly selective method to investigate the neuropharmacological underpinnings of the interoceptive effects of drugs. Historically, drug discrimination has been one of the most widely used assays in the field of behavioral pharmacology. Drug-discrimination procedures have also been adapted for use with humans and are conceptually similar to preclinical drug-discrimination techniques in that a behavior is differentially reinforced contingent on the presence or absence of a specific interoceptive drug stimulus. This review gives some general history and background concerning the major theoretical concepts and principles of drug-discrimination research as well as its relevance to substance-use disorders. This article also provides a procedural overview and discusses key methodological issues that must be considered when designing and conducting a human drug-discrimination study. Although drug discrimination is unequivocally one of the most sophisticated and useful behavioral assays to investigate the underlying neuropharmacology of drugs in vivo, enthusiasm for its use has steadily declined in the last decade and a half. We conclude by commenting on the current state of drug-discrimination research and suggest potential avenues for future drug-discrimination research.
| Original language | English |
|---|---|
| Pages (from-to) | 214-228 |
| Number of pages | 15 |
| Journal | Experimental and Clinical Psychopharmacology |
| Volume | 24 |
| Issue number | 4 |
| DOIs | |
| State | Published - Aug 1 2016 |
Bibliographical note
Publisher Copyright:© 2016 American Psychological Association.
Funding
Support for Dr. Garcia-Romeu was provided by National Institute on Drug Abuse Grant T32DA07209 and the Heffter Research Institute. The funding sources had no role other than financial support. We thank Toni White, B.A., for her meticulous work in organizing and editing the references in this article. All authors contributed in a significant way to the manuscript. All authors have read and approved the final manuscript
| Funders | Funder number |
|---|---|
| National Institute on Drug Abuse | R56DA041201, T32DA07209 |
| Heffter Research Institute |
Keywords
- Drug discrimination
- Humans
- Neuropharmacology
- Subject-rated effects
- Substance-use disorders
ASJC Scopus subject areas
- Pharmacology
- Psychiatry and Mental health
- Pharmacology (medical)